Gilead Sciences has exercised its option to acquire a 49.9 percent stake in Pionyr Immunotherapeutics Inc. for $275 million, and has an exclusive option to acquire the remainder of Pionyr. Pionyr’s shareholders may receive up to an additional $1.47 billion in option exercise fees and future milestone payments. Pionyr’s Myeloid Tuning therapies have the potential to treat patients who currently do not benefit from checkpoint inhibitor therapies. PY314 and PY159 have demonstrated preclinical ef...